Treatment rationale study design for the MetLung trial: A randomized, double-blind phase III study of onartuzumab (MetMAb) in combination with erlotinib versus erlotinib alone in patients who have received standard chemotherapy for stage IIIB or IV met-positive non-small-cell lung cancer

1. Spigel, D.R.
2. Edelman, M.J.
3. Mok, T.
4. O'Byrne, K.
5. Paz-Ares, L.
6. Yu, W.
7. Rittweger, K.
8. Thurm, H.